Physician profile
Brian Willis
NPI 1770363178
$1,462.78
in general payments reported to CMS, 2019-2025
24 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $91.02 · 2024: $1,077 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $283.61 | 2024-2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $138.88 | 2025 | Twiist |
| Lilly USA, LLC | $137.77 | 2024 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $90.21 | 2023-2024 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $69.25 | 2023-2024 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.58 | 2024 | Synjardy, Jardiance |
| Tandem Diabetes Care, INC. | $64.20 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $58.92 | 2024 | Korlym |
| Insulet Corporation | $51.16 | 2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $47.16 | 2024 | Recorlev, Gvoke Hypopen |
| Kyowa Kirin, INC. | $46.73 | 2023-2024 | Crysvita |
| Abbvie INC. | $46.61 | 2024 | |
| Beta Bionics, INC. | $44.95 | 2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $41.83 | 2024 | Wegovy |
| Amgen INC. | $41.53 | 2024 | Evenity, Prolia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $35.41 | 2024 | Xyosted |
| Mannkind Corporation | $34.84 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.40 | 2024 | |
| Alexion Pharmaceuticals, INC. | $32.11 | 2024 | Strensiq |
| Ascensia Diabetes Care US INC. | $30.73 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.64 | 2024 | |
| Radius Health, INC. | $17.71 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $14.03 | 2024 | |
| Theracosbio, LLC | $11.52 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.